A Study of Chemotherapy-induced Peripheral Neuropathy in Hodgkin's Lymphoma Patients who Received Brentuximab Vedotin

Overview

About this study

The purpose of this study is to provide a summary of results of an oral survey of subjects with Hodgkin’s lymphoma who were treated with brentuximab vedotin.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Living adults with a diagnosis of Hodgkin’s lymphoma who have received brentuximab vedotin.

Exclusion Criteria: 

  • Subjects who do not meet the above criteria.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Ansell, M.D., Ph.D.

Contact us for the latest status

Contact information:

Kay Ristow

(507) 284-9168

Ristow.Kay@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions